CONMED Corporation — Third Quarter 2026 Earnings Summary

CONMED Corporation reported third-quarter 2026 net sales of $335.6 million, representing a 0.7% year-over-year decrease on a reported basis. Excluding the impact of strategic exits from gastroenterology product offerings, organic constant currency net sales increased by 6.7%, driven by growth in both Orthopedic and General Surgery segments. Diluted earnings per share rose to $0.66, while adjusted diluted earnings per share were $1.04. The company updated its full-year 2026 guidance, projecting net sales between $1.360 billion and $1.366 billion and adjusted diluted EPS between $4.54 and $4.61.